ENTA
Enanta Pharmaceuticals, Inc.
$13.70
-0.55
(-3.86%)
Mkt Cap
318.07M
Volume
179,224
52W Range
6.435-17.15
Sector
Healthcare
Beta
0.97
EPS (TTM)
-2.74
P/E Ratio
-3.12
Revenue (TTM)
69.21M
Rev Growth (5Y)
-11.8%
EPS Growth (5Y)
N/A
Company Description
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.32M | 67.64M | 79.20M | 86.16M | 97.07M | 122.47M | 205.20M | 206.62M | 102.81M | 88.27M | 160.88M | 47.74M |
| Net Income | (81.89M) | (116.05M) | (133.82M) | (121.75M) | (79.00M) | (36.17M) | 46.38M | 71.96M | 17.71M | 21.67M | 78.99M | 34.44M |
| EPS | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 | 1.88 |
| Free Cash Flow | (32.17M) | (96.71M) | (112.21M) | (86.91M) | (70.75M) | 5.64M | 66.00M | 26.24M | 50.15M | 31.07M | 74.34M | 19.15M |
| FCF / Share | -1.51 | -4.57 | -5.35 | -4.22 | -3.51 | 0.28 | 3.37 | 1.27 | 2.63 | 1.64 | 3.98 | 1.04 |
| Operating CF | (19.27M) | (78.76M) | (103.15M) | (84.78M) | (70.00M) | 7.09M | 71.42M | 29.22M | 52.65M | 35.81M | 76.67M | 20.18M |
| Total Assets | 280.73M | 376.65M | 462.27M | 380.59M | 440.86M | 490.79M | 489.83M | 414.23M | 326.64M | 281.28M | 246.01M | 155.41M |
| Total Debt | 201.06M | 226.06M | 26.51M | 26.69M | 6.83M | 9.58M | 200,000 | 293,000 | 458,000 | 531,000 | 598,000 | 200,000 |
| Cash & Equiv | 32.30M | 37.23M | 85.39M | 43.99M | 57.21M | 87.13M | 51.23M | 63.90M | 65.67M | 16.58M | 21.73M | 30.70M |
| Book Value | 64.72M | 128.81M | 216.74M | 321.33M | 399.43M | 455.58M | 462.49M | 393.68M | 301.68M | 269.94M | 236.16M | 148.65M |
| Return on Equity | -1.27 | -0.90 | -0.62 | -0.38 | -0.20 | -0.08 | 0.10 | 0.18 | 0.06 | 0.08 | 0.33 | 0.23 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.16M | 18.61M | 15.12M | 18.31M | 14.93M | 16.96M | 14.61M | 17.97M | 17.05M | 18.00M | 18.93M | 18.89M |
| Net Income | (13.09M) | (11.94M) | (18.70M) | (18.25M) | (22.64M) | (22.29M) | (28.82M) | (22.66M) | (31.16M) | (33.41M) | (28.11M) | (39.06M) |
| EPS | -0.45 | -0.56 | -0.87 | -0.86 | -1.06 | -1.05 | -1.36 | -1.07 | -1.47 | -1.58 | -1.33 | -1.86 |
| Free Cash Flow | (7.17M) | (11.84M) | (7.95M) | 17.35M | (16.03M) | (25.55M) | (19.35M) | (21.32M) | (30.27M) | (25.77M) | (22.97M) | (34.28M) |
| FCF / Share | -0.34 | -0.55 | -0.37 | 0.81 | -0.75 | -1.20 | -0.91 | -1.01 | -1.43 | -1.22 | -1.09 | -1.63 |
| Operating CF | (7.16M) | (11.70M) | (6.49M) | 17.51M | (13.49M) | (16.80M) | (10.40M) | (14.78M) | (28.60M) | (24.99M) | (21.60M) | (32.13M) |
| Total Assets | 314.70M | 329.50M | 280.73M | 301.03M | 322.99M | 348.64M | 376.65M | 398.82M | 413.56M | 428.50M | 462.27M | 495.17M |
| Total Debt | 186.62M | 193.18M | 201.06M | 207.10M | 216.14M | 221.29M | 226.06M | 226.17M | 229.86M | 220.00M | 222.44M | 230.80M |
| Cash & Equiv | 34.93M | 37.44M | 32.30M | 44.81M | 60.21M | 84.35M | 37.23M | 35.77M | 63.54M | 39.93M | 85.39M | 95.18M |
| Book Value | 116.59M | 126.59M | 64.72M | 79.28M | 93.54M | 111.82M | 128.81M | 148.91M | 166.11M | 191.88M | 216.74M | 237.82M |
| Return on Equity | -0.11 | -0.09 | -0.29 | -0.23 | -0.24 | -0.20 | -0.22 | -0.15 | -0.19 | -0.17 | -0.13 | -0.16 |
ENTA News
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria